jobs

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by GRAIL, LLC

GRAIL to Host Capital Markets Day
From GRAIL, LLC
Via Business Wire
GRAIL Presents New Data on Galleri® and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting
From GRAIL, LLC
Via Business Wire
GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
From GRAIL, LLC
Via Business Wire
Curative Insurance Company Adds GRAIL’s Galleri® Test to Member Benefits for Multi-Cancer Early Detection
From GRAIL, LLC
Via Business Wire
GRAIL Partners With Professional Golfers Steve Stricker and Juli Inkster to Raise Awareness of Multi-Cancer Early Detection at Second Annual Galleri Classic PGA TOUR Champions Tournament
From GRAIL, LLC
Via Business Wire
BeniComp to Offer GRAIL’s Multi-Cancer Early Detection Test for Employee Health Screening
From GRAIL, LLC
Via Business Wire
Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at North America Conference on Lung Cancer
From GRAIL, LLC
Via Business Wire
GRAIL To Initiate REACH Study To Evaluate Clinical Impact Of GalleriⓇ Multi-Cancer Early Detection (MCED) Test Among The Medicare Population
From GRAIL, LLC
Via Business Wire
Final Results From PATHFINDER Study of GRAIL’s Multi-Cancer Early Detection Blood Test Published in The Lancet
From GRAIL, LLC
Via Business Wire
Point32Health and GRAIL Expand Pilot Access to Galleri® Multi-Cancer Early Detection Blood Test
From GRAIL, LLC
Via Business Wire
Whitman-Walker Institute, Cancer Support Community and GRAIL Collaborate On Research Aimed at Advancing Health Equity in Cancer Screening and Care Through Multi-Cancer Early Detection
From GRAIL, LLC
Via Business Wire
The Lancet Oncology Publishes Results from SYMPLIFY, The First Prospective Study of a Multi-Cancer Early Detection Test in a Symptomatic Patient Population
From GRAIL, LLC
Via Business Wire
New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing
From GRAIL, LLC
Via Business Wire
GRAIL and University of Oxford to Present Results From First Prospective Study of Multi-Cancer Early Detection in a Symptomatic Patient Population at 2023 ASCO Annual Meeting
From GRAIL, LLC
Via Business Wire
GRAIL to Present New Multi-Cancer Early Detection Data at the 2023 ASCO Annual Meeting
From GRAIL, LLC
Via Business Wire
GRAIL Presents Positive Analytical Validation Data on its Methylation-Based Post-Diagnostic Cancer Research Solution at American Association for Cancer Research (AACR) Annual Meeting 2023
From GRAIL, LLC
Via Business Wire
GRAIL Presents New Data Demonstrating That Methylation Assay Detects Residual Hematologic Cancer After Treatment at American Association for Cancer Research (AACR) Annual Meeting 2023
From GRAIL, LLC
Via Business Wire
GRAIL Showcases Methylation Platform Performance Across Cancer Continuum With New Data at American Association for Cancer Research (AACR) Annual Meeting
From GRAIL, LLC
Via Business Wire
Providence and GRAIL Expand Partnership to Increase Access to Galleri® Multi-Cancer Early Detection Screening
From GRAIL, LLC
Via Business Wire
GRAIL Teams Up with Professional Golfers David Duval and Juli Inkster to Raise Awareness of Multi-Cancer Early Detection
From GRAIL, LLC
Via Business Wire
Grail Introduces State-of-the-Art Methylation-Based Solution to Accelerate Cancer Research in the Post-Diagnosis Setting
From GRAIL, LLC
Via Business Wire
Point32Health and GRAIL Expand Galleri® Multi-Cancer Early Detection Blood Test Pilot to Harvard Pilgrim Health Care Members on the Maine Health Insurance Marketplace
From GRAIL, LLC
Via Business Wire
GRAIL CCGA Discovery Results Published in Cancer Cell Reveal Methylation as Promising DNA Hallmark for Multi-Cancer Early Detection
From GRAIL, LLC
Via Business Wire
Tickers ILMN
GRAIL and Carrum Health Partner to Include Galleri® as Part of Comprehensive Cancer Care Offering to Employers
From GRAIL, LLC
Via Business Wire
CORRECTING and REPLACING GRAIL Announces Final Results From the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022
From GRAIL, LLC
Via Business Wire
GRAIL to Present Final Multi-cancer Early Detection Data From the Interventional PATHFINDER Study at ESMO Congress 2022
From GRAIL, LLC
Via Business Wire
Grail and National Health Service (NHS) England Complete Enrollment of 140,000 Participants in Largest Study of Multi-Cancer Early Detection Test
From GRAIL, LLC
Via Business Wire
Mercy Offers New GRAIL Blood Test to Detect 50+ Types of Cancer
From GRAIL, LLC
Via Business Wire
GRAIL and England’s National Health Service (NHS) Present Trial Design for Largest Study of Multi-Cancer Early Detection Test at ASCO Annual Meeting
From GRAIL, LLC
Via Business Wire
GRAIL and Ochsner Health Launch New Initiatives to Improve Cancer Detection Rates in Louisiana
From GRAIL, LLC
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News Instagram Instagram
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

922 Allowance Ave SE
Medicine Hat, AB T1A 3G7

Office hours: 8:30 a.m.-4:30 p.m. Monday to Friday, closed Saturday Sunday and statutory holidays.

[P] 403.527.1101
[F] 403-527-0737

Print Advertising: 403.528.5659
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2024 The Medicine Hat News